HIV, Substance Use Disorders
Conditions
Keywords
People Living with HIV, Screening, Substance Use Disorder Screening
Brief summary
This study aims to achieve health equity in substance use disorder (SUD) screening and treatment among people living with human immunodeficiency virus (HIV) by implementing interventions to decrease barriers to screening (clinic-based, in-person) and treatment (referral-focused), a program the study investigators call "Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use (ePORTAL HIV-S)." The ePORTAL HIV-S randomized control trial will focus on portal-based screening in the HIV clinic, regardless of whether the patient has a scheduled appointment with their HIV provider.
Detailed description
Substance use disorder (SUD) and human immunodeficiency virus (HIV) are synergistic epidemics (syndemics) disproportionately affecting Black Americans. Structural racism related to inadequate access to healthcare, stigma, and criminalization, especially among those with intersectional identities related to gender and sexual minorities, further exacerbate disparities in HIV and SUD outcomes. SUD is often unrecognized and untreated among people living with HIV (PLWH). Only about half of HIV care sites routinely screen and refer to SUD treatment. In preliminary work, the study investigators found that nearly half of patients assessed in a HIV clinic waiting room met the criteria for a SUD, but 65% had not been diagnosed with SUD. A promising strategy to address structural barriers to SUD screening for PLWH is use of electronic patient portals. Patient portals are secure websites that give patients access to health information and allow for secure messaging with providers. They are associated with improved health outcomes and patient engagement. Notably, while most SUD screening currently occurs during clinic visits, portals can be utilized for SUD screening to reach patients who miss clinic visits, which is more common among people with HIV and SUD. The study team's preliminary work has demonstrated the potential of the portal for use in a population health approach to behavioral health screening. This study will implement and evaluate multi-level interventions to decrease barriers to SUD screening (clinic-based, in-person) and treatment (referral-focused), a program the study investigators call "Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use (ePORTAL HIV-S)." ePORTAL HIV-S is conducting a randomized control trial to assess the effectiveness of population health vs. usual (clinic-visit) SUD screening among PLWH in a HIV clinic.
Interventions
Participants 18 years or older, with an active patient portal account, who have attended a HIV care clinic visit in the HIV clinic in the last two years and have not completed the validated NIDA Quick Screen V1.0 in the previous year will be eligible for intervention randomization. Those randomized into the intervention group will receive the validated NIDA Quick Screen V1.0 over their patient portal account. Participants randomized to this group can complete the screener over the patient portal without a scheduled appointment with their HIV clinician.
Participants randomized to the usual care group will receive the validated NIDA Quick Screen V1.0 during routine in-clinic visits if they attend their scheduled visit. The medical assistant will ask participants to complete the NIDA Quick Screen V1.0. Participants who endorse the use of illegal drugs or prescription drugs for non-medical reasons, tobacco use, or heavy drinking will be referred to SUD treatment.
Sponsors
Study design
Masking description
Patient randomization will be completed by an honest broker and blinded to the research team.
Intervention model description
Participants will be enrolled into two groups: intervention and standard care. Patients randomized to the intervention arm will not be blinded to the intervention and will receive the NIDA Quick Screen via MyChart and at clinic appointments. Patients randomized to the usual care group will receive the NIDA Quick Screen during appointments with their clinicians and, thus, be blinded to trial assignments. HIV clinicians have been informed of the intervention and will not be informed of the randomization assignment. Still, clinicians will receive NIDA Quick Screen results when the patient completes the screener via MyChart.
Eligibility
Inclusion criteria
* 18 years or older * has been diagnosed with human immunodeficiency virus infection (HIV) * provider has assented * receives HIV care at the University of Chicago Ryan White Adult HIV Care Clinic, as evidenced by inclusion in the Epic HIV Registry * speaks English * has not completed in clinic SUD screening in the last year * has an active MyChart account
Exclusion criteria
* Patients who have been screened for substance use disorder at the clinic in the last year using the NIDA Quick Screen * Patient's provider has not assented to the intervention * Patient is younger than 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants screened for substance use disorder | 1 year from screening start date | Percentage of participants who completed the validated NIDA Quick Screen V1.0 for substance use disorder in the HIV clinic. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Retention in care in the year post-screening | 2 years from screening start date | \# of participants who attended HIV care clinic visit in the year after completing the NIDA Quick Screen V1.0 |
| HIV viral suppression | 1 year from screening start date | Participants' labs of HIV viral load measurements |
| Number and percentage of participants referred to substance use and misuse treatment | 1 year from screening start date | \# of participants referred to substance use and misuse treatment / # of participants diagnosed with moderate or high risk of substance use involvement |
| Number and percentage of participants with moderate or high risk of substance involvement | 1 year from screening start date | The number and percentage of participants who receive a score of 4 or higher in illicit substance use, say "Yes" to one or more days of heavy drinking, or endorse tobacco use, indicating moderate or high risk of substance involvement measured by the NIDA Quick Screen V1.0. |
Countries
United States
Contacts
University of Chicago
University of Chicago